Abstract
Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.
| Original language | English |
|---|---|
| Pages (from-to) | 2302-2303 |
| Number of pages | 2 |
| Journal | Annals of Oncology : Official Journal of the European Society for Medical Oncology |
| Volume | 27 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 1 Dec 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver